
BR.31
NCT02273375
BR.31
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer
Status:
Closed to Accrual

III
Phase

Adjuvant
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
PD-1, PD-L1, EGFR, ALK
Investigational
Product
Durvalumab (MEDI4736)
Anti-PD-L1 Monoclonal Antibody (i.v.)
Treatment Arms
o Experimental: MEDI4736
o Placebo Comparator: Placebo